With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible, and keeping that very thought in mind, we collated a list of 54 drugs that are going off-patent in 2024. We also included yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose the most profitable drug to develop a generic version of.
Loved the idea and the list? Thank us later in the comments section. Now onto the list.
The article has a list of drug patents expiring in 2024. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
Drug Patent Expiration Report
Download the Drug Expiration Report 2026-2030 in PDF:
Mulpleta
Lusutrombopag
Sales:
200 Million Yen (2018)
| Patents | Expiration Date |
|---|---|
| US7601746 | September 05, 2024 |
| US8889722 | July 29, 2028 |
| US8530668 | January 21, 2030 |
Dosage: Oral
Company: Shionogi Inc.
Ingredients: LUSUTROMBOPAG
Treatment: Thrombocytopenia
Invokamet XR
Canagliflozin; Metformin Hydrochloride
Sales:
$1.41 Billion (2016)
| Patents | Expiration Date |
|---|---|
| US8785403 | July 30, 2024 |
| US8222219 | March 11, 2025 |
Dosage: Tablet, Extended Release; Oral
Company: Janssen Pharmaceuticals Inc
Ingredients: Canagliflozin; Metformin Hydrochloride
Treatment: Type 2 Diabetes Mellitus
Revlimid
Lenalidomide
Sales:
$10.82 Billion (2019)
| Patents | Expiration Date |
|---|---|
| US7855217 | November 24, 2024 |
| US7465800 | April 27, 2027 |
Dosage: Oral
Company: Celgene Corp
Ingredients: LENALIDOMIDE
Treatment: Multiple Myeloma and Myelodysplastic Syndromes
Rydapt
Midostaurin
Sales:
$150 Million (2018)
| Patents | Expiration Date |
|---|---|
| US7973031 | October 17, 2024 |
| US8222244 | October 29, 2022 |
Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Midostaurin
Treatment: Acute Myeloid Leukemia
Prevymis
Letermovir
Sales:
$370 Million (2020)
| Patents | Expiration Date |
|---|---|
| US7196086 | May 22, 2024 |
| US8513255 | May 22, 2024 |
Dosage: Solution; Intravenous
Company: Merck Sharp And Dohme Corp
Ingredients: Letermovir
Treatment: Cytomegalovirus (CMV) infection
Vyndaqela
Tafamidis Meglumine
Sales:
$259 Million (Jan-Sep 2019)
| Patents | Expiration Date |
|---|---|
| US7214695 | April 27, 2024 |
| US7214696 | December 19, 2023 |
| US8168663 | December 19, 2023 |
| US8653119 | January 28, 2024 |
Dosage: Capsule; Oral
Company: Foldrx Pharmaceuticals Inc Sub Pfizer Inc
Ingredients: Tafamidis Meglumine
Treatment: Transthyretin Amyloid Polyneuropathy
Lynparza
Olaparib
Sales:
$259 Million (Jan-Sep 2019)
| Patents | Expiration Date |
|---|---|
| US7151102 | April 29, 2022 |
| US7449464 | October 11, 2024 |
| US7981889 | October 11, 2024 |
| US8912187 | March 12, 2024 |
Dosage: Capsule; Oral
Company: AstraZeneca Pharmaceuticals LP
Ingredients: Olaparib
Treatment: Advanced Ovarian Cancer, Fallopian Tube Cancer
Tasigna
Nilotinib
Sales:
$1.88 Billion (2019)
| Patents | Expiration Date |
|---|---|
| US7169791 | January 04, 2024 |
| US8415363 | January 18, 2027 |
| US8163904 | February 23, 2029 |
| US9061029 | October 7, 2032 |
Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Nilotinib Hydrochloride
Treatment: Chronic Myelogenous Leukemia
Xopenex HFA
Levalbuterol Tartrate
Sales:
$148 Million (2012)
| Patents | Expiration Date |
|---|---|
| US7256310 | October 08, 2024 |
Dosage: Aerosol, Metered; Inhalation
Company: Sunovion Pharmaceuticals Inc
Ingredients: Levalbuterol Tartrate
Treatment: Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Vandazole
Metronidazole
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7456207 | September 22, 2024 |
Dosage: Gel; Vaginal
Company: Teva Pharmaceuticals USA
Ingredients: Metronidazole
Treatment: Bacterial Vaginosis
Prialt
Ziconotide Acetate
Sales:
$27 Million (2017)
| Patents | Expiration Date |
|---|---|
| US8653033 | October 10, 2024 |
| US8765680 | October 10, 2024 |
| US9707270 | October 10, 2024 |
Dosage: Injectable; Intrathecal
Company: TerSera Therapeutics LLC
Ingredients: Ziconotide Acetate
Treatment: Pain Reliever
Aloxi
Palonosetron Hydrochloride
Sales:
$400 Million (2019)
| Patents | Expiration Date |
|---|---|
| US7947724 | January 30, 2024 |
| US7947725 | January 30, 2024 |
| US7960424 | January 30, 2024 |
| US8518981 | January 30, 2024 |
| US8598218 | January 30, 2024 |
| US9173942 | January 30, 2024 |
| US9439854 | January 30, 2024 |
| US9457020 | January 30, 2024 |
Dosage: Injectable; Intravenous
Company: Helsinn Healthcare SA
Ingredients: Palonosetron Hydrochloride
Treatment: Acute Nausea and Vomiting
Dificid
Fidaxomicin
Sales:
$60 Million (2021)
| Patents | Expiration Date |
|---|---|
| US8586551 | January 23, 2024 |
| US7378508 | January 31, 2028 |
| US7863249 | January 31, 2028 |
Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: FIDAXOMICIN
Treatment: Clostridioides difficile-associated Diarrhea (CDAD)
Linzess
Linaclotide
Sales:
$287 Million (2021)
| Patents | Expiration Date |
|---|---|
| US7371727 | January 28, 2024 |
| US7745409 | January 28, 2024 |
| US8080526 | January 28, 2024 |
| US7704947 | January 28, 2024 |
| US7304036 | August 30, 2026 |
Dosage: Oral
Company: Allergan
Ingredients: LINACLOTIDE
Treatment: Irritable Bowel Syndrome
Myfembree
Relugolix/estradiol/norethisterone acetate
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7300935 | January 28, 2024 |
| US8058280 | January 28, 2024 |
Dosage: Oral
Company: Myovant Sciences
Ingredients: ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Treatment: Heavy Menstrual Bleeding
Ferric Citrate
Ferric Citrate
Sales:
–
| Patents | Expiration Date |
|---|---|
| US9328133 | February 18, 2024 |
| US9757416 | February 18, 2024 |
| US8338642 | February 18, 2024 |
| US7767851 | February 18, 2024 |
Dosage: Oral
Company: Akebia Therapeutics
Ingredients: FERRIC CITRATE
Treatment: Hyperphosphataemia and Iron Deficiency Anaemia
Ofev/Vargatef
Nintedanib
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7119093 | February 21, 2024 |
| US6762180 | October 1, 2025 |
Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: NINTEDANIB ESYLATE
Treatment: Idiopathic Pulmonary Fibrosis
Isentress
Raltegravir
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7119093 | February 21, 2024 |
| US6762180 | October 1, 2025 |
Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS
Zontivity
Vorapaxar
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7304078 | April 6, 2024 |
| US7713999 | May 30, 2024 |
Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: VORAPAXAR SULFATE
Treatment: Peripheral Arterial Disease
Bosulif
Bosutinib
Sales:
$23 Million (2020)
| Patents | Expiration Date |
|---|---|
| USRE42376 | April 13, 2024 |
| US7767678 | November 23, 2026 |
Dosage: Oral
Company: Pfizer
Ingredients: BOSUTINIB MONOHYDRATE
Treatment: Chronic Myelogenous Leukemia
Omontys
Peginesatide
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7084245 | May 12, 2024 |
| US7414105 | May 12, 2024 |
| US7919118 | May 12, 2024 |
| US7528104 | May 12, 2024 |
Dosage: Subcutaneous, intravenous
Company: Affymax Inc.
Ingredients: PEGINESATIDE ACETATE
Treatment: Anemia
Aliqopa
Copanlisib
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7511041 | May 13, 2024 |
| USRE46856 | October 22, 2029 |
| US10383876 | March 29, 2032 |
Dosage: Intravenous infusion
Company: Bayer
Ingredients: COPANLISIB DIHYDROCHLORIDE
Treatment: Relapsed follicular lymphoma
Mayzent
Siponimod
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7939519 | May 19, 2024 |
Dosage: Oral
Company: Novartis
Ingredients: SIPONIMOD FUMARIC ACID
Treatment: Multiple Sclerosis
Prevymis
Letermovir
Sales:
$281 Million (2020)
| Patents | Expiration Date |
|---|---|
| US8513255 | May 22, 2024 |
| USRE46791 | May 22, 2024 |
Dosage: Oral, Intravenous
Company: Merck & Co
Ingredients: LETERMOVIR
Treatment: Cytomegalovirus
Xifaxan
Rifaximin
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7612199 | June 19, 2024 |
| US8835452 | June 19, 2024 |
| US8158781 | June 19, 2024 |
| US7045620 | June 19, 2024 |
| US7902206 | June 19, 2024 |
| US7906542 | June 1, 2025 |
| US8741904 | February 27, 2026 |
| US8193196 | September 2, 2027 |
Dosage: Oral
Company: Salix Pharmaceuticals
Ingredients: RIFAXIMIN
Treatment: Travelers’ Diarrhea, Irritable Bowel Syndrome
Remodulin/Orenitram/Tyvaso
Treprostinil
Sales:
–
| Patents | Expiration Date |
|---|---|
| US9050311 | May 24, 2024 |
| US7417070 | July 30, 2026 |
| US8497393 | December 15, 2028 |
Dosage: Subcutaneous, intravenous, inhalation, Oral
Company: United Therapeutics
Ingredients: TREPROSTINIL DIOLAMINE
Treatment: Pulmonary arterial hypertension
Tpoxx
Tecovirimat
Sales:
–
| Patents | Expiration Date |
|---|---|
| US8124643 | June 18, 2024 |
| US9339466 | March 23, 2031 |
Dosage: Oral
Company: SIGA Technologies
Ingredients: TECOVIRIMAT
Treatment: Orthopoxviruses (Smallpox and Monkeypox)
Nuvigil
Armodafinil
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7132570 | June 18, 2024 |
Dosage: Oral
Company: Teva Pharmaceuticals
Ingredients: ARMODAFINIL
Treatment: Excessive Daytime Sleepiness
Oriahnn
Elagolix/estradiol/norethindrone acetate
Sales:
$145 Million (2021)
| Patents | Expiration Date |
|---|---|
| US7419983 | July 6, 2024 |
| US7056927 | September 10, 2024 |
Dosage: Oral
Company: AbbVie Inc.
Ingredients: ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
Treatment: Heavy Menstrual Bleeding
Xeglyze
Abametapir
Sales:
–
| Patents | Expiration Date |
|---|---|
| US9839631 | July 16, 2024 |
Dosage: Topical
Company: Dr. Reddy’s Laboratories
Ingredients: ABAMETAPIR
Treatment: Head Lice Infestation
Ninlaro
Ixazomib
Sales:
–
| Patents | Expiration Date |
|---|---|
| US8546608 | August 12, 2024 |
| US8003819 | August 6, 2027 |
| US8530694 | August 6, 2027 |
| US7687662 | August 6, 2027 |
| US8859504 | June 16, 2029 |
| US7442830 | November 20, 2029 |
Dosage: Oral
Company: Takeda
Ingredients: IXAZOMIB CITRATE
Treatment: Multiple Myeloma
Prezista
Darunavir
Sales:
–
| Patents | Expiration Date |
|---|---|
| US8518987 | August 16, 2024 |
| US7700645 | June 26, 2027 |
Dosage: Oral
Company: Janssen Therapeutics
Ingredients: DARUNAVIR
Treatment: HIV/AIDS
Xarelto
Rivaroxaban
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7157456 | August 28, 2024 |
Dosage: Oral
Company: Janssen Therapeutics
Ingredients: RIVAROXABAN
Treatment: Blood clots
MoviPrep
POLYETHYLENE GLYCOL 3350
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7169381 | September 1, 2024 |
| US7658914 | September 1, 2024 |
Dosage: Oral
Company: Velinor A.G
Ingredients: ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE
Treatment: Use for Colonoscopy Bowel Preparation
Aldara
Imiquimod
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7696159 | October 1, 2024 |
Dosage: Topical
Company: 3M Pharmaceutical
Ingredients: IMIQUIMOD
Treatment: Genital Warts, Superficial Basal cell carcinoma, and Actinic Keratosis
Brilinta
Ticagrelor
Sales:
$1.4 Billion (2021)
| Patents | Expiration Date |
|---|---|
| USRE46276 | October 30, 2024 |
Dosage: Oral
Company: AstraZeneca
Ingredients: TICAGRELOR
Treatment: Stroke, Heart Attack
Xiidra
Lifitegrast
Sales:
$1.4 Billion (2021)
| Patents | Expiration Date |
|---|---|
| US7745460 | November 5, 2024 |
| US7928122 | November 5, 2024 |
| US7314938 | March 10, 2025 |
| US8084047 | May 17, 2026 |
| US9890141 | October 21, 2030 |
Dosage: Eye Drops
Company: Novartis
Ingredients: LIFITEGRAST
Treatment: Signs and Symptoms of Dry Eye
Nourianz
Istradefylline
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7541363 | November 13, 2024 |
Dosage: Oral
Company: Kyowa Kirin Co.
Ingredients: ISTRADEFYLLINE
Treatment: Levodopa/Carbidopa in adults with Parkinson’s disease
Ponvory
Ponesimod
Sales:
–
| Patents | Expiration Date |
|---|---|
| USRE43728 | November 16, 2024 |
| US9062014 | May 6, 2032 |
Dosage: Oral
Company: Janssen Pharmaceuticals
Ingredients: PONESIMOD
Treatment: Multiple Sclerosis
Tukysa
Tucatinib
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7452895 | November 16, 2024 |
| US8648087 | April 12, 2031 |
Dosage: Oral
Company: Seagen Inc
Ingredients: TUCATINIB
Treatment: HER2-positive Breast Cancer
Asclera/Aethoxysklerol/Varithena
Polidocanol
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7731986 | November 17, 2024 |
Dosage: Topical, Subcutaneous Injection
Company: Methapharm, Inc.
Ingredients: POLIDOCANOL
Treatment: Itching caused by Eczema and Dry Skin
Zepzelca
Lurbinectedin
Sales:
–
| Patents | Expiration Date |
|---|---|
| US7763615 | December 13, 2024 |
Dosage: Intravenous Injection
Company: PharmaMar, S.A.
Ingredients: LURBINECTEDIN
Treatment: Metastatic Small Cell Lung Cancer (SCLC)
Victrelis
Boceprevir
Sales:
–
| Patents | Expiration Date |
|---|---|
| USRE43298 | December 22, 2024 |
Dosage: Oral
Company: Merck & Co
Ingredients: BOCEPREVIR
Treatment: Hepatitis caused by Hepatitis C virus (HCV) genotype 1
